Cargando…
Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment
The clinical presentation of Human African Trypanosomiasis (HAT) due to Trypanosoma brucei gambiense is well known, but knowledge on long-term sequelae is limited. In the frame of studies conducted between 2004 and 2005 in the Democratic Republic of the Congo (DRC), the prevalence of HAT related sig...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157708/ https://www.ncbi.nlm.nih.gov/pubmed/31940846 http://dx.doi.org/10.3390/tropicalmed5010010 |
_version_ | 1783522404306255872 |
---|---|
author | Mudji, Junior Blum, Anna Grize, Leticia Wampfler, Rahel Ruf, Marie-Thérèse Cnops, Lieselotte Nickel, Beatrice Burri, Christian Blum, Johannes |
author_facet | Mudji, Junior Blum, Anna Grize, Leticia Wampfler, Rahel Ruf, Marie-Thérèse Cnops, Lieselotte Nickel, Beatrice Burri, Christian Blum, Johannes |
author_sort | Mudji, Junior |
collection | PubMed |
description | The clinical presentation of Human African Trypanosomiasis (HAT) due to Trypanosoma brucei gambiense is well known, but knowledge on long-term sequelae is limited. In the frame of studies conducted between 2004 and 2005 in the Democratic Republic of the Congo (DRC), the prevalence of HAT related signs and symptoms were evaluated before the start of treatment and at the end of treatment. To explore possible long-term sequelae, the same clinical parameters were assessed in 2017 in 51 first stage and 18 second stage HAT patients. Signs and symptoms 12–13 years after treatment were compared to before and immediately after treatment and to controls matched for sex and age (±5 years). In first stage HAT patients, the prevalence of all signs and symptoms decreased compared to before treatment but were still higher after 12–13 years than immediately at the end of treatment and in the control group. In second stage HAT patients, all HAT-specific findings had continuously decreased to the point where they were in the range of the healthy control group. In a selection of oligosymptomatic first stage HAT patients, no trypanosomes were detected in the blood by microscopic examination or PCR. An oligosymptomatic presentation of HAT due to the persistence of parasites in compartments, where first stage HAT medications do not penetrate, could not be ruled out. |
format | Online Article Text |
id | pubmed-7157708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71577082020-04-21 Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment Mudji, Junior Blum, Anna Grize, Leticia Wampfler, Rahel Ruf, Marie-Thérèse Cnops, Lieselotte Nickel, Beatrice Burri, Christian Blum, Johannes Trop Med Infect Dis Article The clinical presentation of Human African Trypanosomiasis (HAT) due to Trypanosoma brucei gambiense is well known, but knowledge on long-term sequelae is limited. In the frame of studies conducted between 2004 and 2005 in the Democratic Republic of the Congo (DRC), the prevalence of HAT related signs and symptoms were evaluated before the start of treatment and at the end of treatment. To explore possible long-term sequelae, the same clinical parameters were assessed in 2017 in 51 first stage and 18 second stage HAT patients. Signs and symptoms 12–13 years after treatment were compared to before and immediately after treatment and to controls matched for sex and age (±5 years). In first stage HAT patients, the prevalence of all signs and symptoms decreased compared to before treatment but were still higher after 12–13 years than immediately at the end of treatment and in the control group. In second stage HAT patients, all HAT-specific findings had continuously decreased to the point where they were in the range of the healthy control group. In a selection of oligosymptomatic first stage HAT patients, no trypanosomes were detected in the blood by microscopic examination or PCR. An oligosymptomatic presentation of HAT due to the persistence of parasites in compartments, where first stage HAT medications do not penetrate, could not be ruled out. MDPI 2020-01-11 /pmc/articles/PMC7157708/ /pubmed/31940846 http://dx.doi.org/10.3390/tropicalmed5010010 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mudji, Junior Blum, Anna Grize, Leticia Wampfler, Rahel Ruf, Marie-Thérèse Cnops, Lieselotte Nickel, Beatrice Burri, Christian Blum, Johannes Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment |
title | Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment |
title_full | Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment |
title_fullStr | Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment |
title_full_unstemmed | Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment |
title_short | Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment |
title_sort | gambiense human african trypanosomiasis sequelae after treatment: a follow-up study 12 years after treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157708/ https://www.ncbi.nlm.nih.gov/pubmed/31940846 http://dx.doi.org/10.3390/tropicalmed5010010 |
work_keys_str_mv | AT mudjijunior gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT blumanna gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT grizeleticia gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT wampflerrahel gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT rufmarietherese gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT cnopslieselotte gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT nickelbeatrice gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT burrichristian gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment AT blumjohannes gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment |